as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹68.54
Change
+0.86 (1.27%)
Open
₹67.2
Prev. Close
₹67.68
Day High
₹69.48
Day Low
₹67.2
Volume Analysis
Traded
873
Delivered
839
Delivery %
96.11%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (1)
- •Low return on equity (3.28%)
Opportunities (1)
- •Strong 3-year revenue growth (25.7%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹71.9 | ₹70.69 | ₹69.62 | ₹68.41 | ₹67.34 | ₹66.13 | ₹65.06 |
| Fibonacci | ₹70.69 | ₹69.82 | ₹69.28 | ₹68.41 | ₹67.54 | ₹67.0 | ₹66.13 |
| Camarilla | ₹69.17 | ₹68.96 | ₹68.75 | ₹68.41 | ₹68.33 | ₹68.12 | ₹67.91 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-0.82%
1 Month
+9.66%
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹72.42
Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
11.25%
Net margin 4.0% × asset turnover 1.13x × equity multiplier 2.49x
Company Overview
Sector
Healthcare
Market Cap
₹36 Cr
P/E (TTM)
9.69
ROE
3.28%
Book Value
₹105.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.
TopFund Analysis
Gkb Ophthalmics Ltd. lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 59/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (3.28%). Strong 3-year revenue growth (25.7%).
TopFund Score — Fundamentals Quality
59/100 — AverageData confidence: 73/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Liquidity
From Screener.in
- +Stock is trading at 0.67 times its book value
- +Company is expected to give good quarter
- +Company has delivered good profit growth of 76.7% CAGR over last 5 years
- −Company has a low return on equity of -4.83% over last 3 years.
- −Company's cost of borrowing seems high
- −Promoter holding has decreased over last 3 years: -8.03%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
GKB Ophthalmics' 44th AGM approved financials, director reappointments, related-party limits, and no dividend for FY26.
44th AGM voting results announced; all 7 resolutions passed with requisite majority on August 25, 2026.
GKB Ophthalmics held its 44th AGM on August 25, 2026; voting results to follow within 48 hours.
Please find attached copies of newspaper cuttings of the extract of Statement of unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, …
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 22 | 20 | 24 | 22 | 26 | 26 | 26 | 31 | 32 | 30 | 57 | 30 | 33 |
| Expenses + | 21 | 21 | 25 | 22 | 25 | 26 | 27 | 34 | 32 | 27 | 55 | 27 | 30 |
| Operating Profit | 1 | 0 | -1 | 0 | 1 | 0 | -1 | -3 | 1 | 3 | 2 | 3 | 3 |
| OPM % | 6.06% | -1.42% | -2.58% | 0.0% | 4.0% | -0.23% | -3.64% | -9.22% | 2.48% | 10.01% | 2.92% | 10.34% | 7.96% |
| Other Income + | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -1 | 1 |
| Interest | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | -1 | -1 | -1 | 0 | -1 | -2 | -4 | -1 | 2 | 1 | 1 | 2 |
| Tax % | 0.0% | 0.0% | 0.0% | 30.43% | 600.0% | 5.45% | 2.69% | 4.82% | 14.29% | 3.66% | -4.41% | -3.7% | 9.76% |
| Net Profit + | 1 | -1 | -1 | -1 | 0 | -1 | -2 | -4 | -1 | 2 | 1 | 1 | 2 |
| EPS in Rs | 1 | -2 | -2 | -2 | -1 | -2 | -4 | -7 | -2 | 3 | 1 | 0 | 2 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 35 | 44 | 76 | 78 | 57 | 59 | 57 | 71 | 75 | 88 | 109 | 149 | 150 |
| Expenses + | 34 | 44 | 75 | 77 | 56 | 56 | 55 | 66 | 72 | 88 | 112 | 140 | 139 |
| Operating Profit | 1 | -1 | 2 | 1 | 1 | 2 | 2 | 5 | 4 | 1 | -3 | 9 | 10 |
| OPM % | 2.4% | -1.6% | 2.5% | 1.7% | 2.0% | 3.6% | 4.0% | 7.0% | 4.9% | 0.6% | -2.5% | 6.0% | 7.0% |
| Other Income + | 1 | 12 | 4 | 0 | 2 | 1 | 2 | 1 | 1 | 2 | 2 | 0 | 1 |
| Interest | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 3 | 2 |
| Depreciation | 2 | 1 | 1 | 2 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | -2 | 8 | 3 | -1 | -2 | -2 | -1 | 2 | 0 | -3 | -7 | 3 | 6 |
| Tax % | -37.0% | 50.0% | 12.0% | -15.0% | -30.0% | 0.0% | -19.0% | 0.0% | 14.0% | 8.0% | 5.0% | 2.0% | — |
| Net Profit + | 0 | 4 | 3 | -1 | -1 | -2 | -1 | 2 | 0 | -3 | -7 | 3 | 6 |
| EPS in Rs | 0 | 10 | 6 | -2 | -2 | -4 | -2 | 3 | 0 | -6 | -14 | 2 | 6 |
| Dividend Payout % | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 36 | 41 | 43 | 41 | 50 | 54 | 58 | 58 | 58 | 55 | 47 | 48 |
| Borrowings + | 9 | 7 | 7 | 10 | 14 | 15 | 12 | 12 | 11 | 11 | 14 | 12 |
| Other Liabilities + | 26 | 17 | 28 | 28 | 25 | 28 | 32 | 35 | 38 | 43 | 59 | 68 |
| Total Liabilities | 75 | 69 | 82 | 83 | 94 | 102 | 107 | 110 | 112 | 114 | 125 | 132 |
| Fixed Assets + | 12 | 13 | 18 | 18 | 26 | 26 | 24 | 23 | 19 | 18 | 17 | 15 |
| CWIP | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 3 | 4 | 4 | 4 | 4 |
| Investments | 16 | 10 | 3 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Other Assets + | 46 | 46 | 60 | 64 | 68 | 75 | 80 | 82 | 87 | 91 | 102 | 111 |
| Total Assets | 75 | 69 | 82 | 83 | 94 | 102 | 107 | 110 | 112 | 114 | 125 | 132 |
| Equity Capital | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 7 | -11 | -3 | -3 | 4 | 3 | 7 | 5 | -3 | 4 | -3 | -4 |
| Cash from Investing Activity + | 0 | 15 | 4 | 1 | -10 | -4 | -17 | -4 | 1 | -2 | 3 | 9 |
| Cash from Financing Activity + | -6 | -3 | -1 | 1 | 13 | 4 | 3 | -2 | -2 | -2 | 1 | -6 |
| Net Cash Flow | 1 | 0 | -1 | 0 | 7 | 4 | -7 | 0 | -4 | 1 | 0 | 0 |
| CFO/OP | 1,117 | 639 | -112 | -190 | 346 | 154 | 300 | 105 | -71 | 865 | 118 | -41 |
| Free Cash Flow | 7 | -13 | -9 | -5 | -6 | 0 | 1 | 0 | -2 | 2 | -6 | -5 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 47.36% | 47.34% | 47.28% | 47.26% | 47.28% | 47.23% | 47.23% | 47.16% | 47.17% | 47.09% | 47.09% | 47.07% |
| Promoters | 50.86% | 50.88% | 50.93% | 50.95% | 50.95% | 50.98% | 50.99% | 51.06% | 51.06% | 51.13% | 51.13% | 51.15% |
| FII | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Gkb Ophthalmics Ltd. (this stock) | 36 | 9.69 | 0.66 | 3.28% |
| Vivo Bio Tech Ltd. | 38 | — | 0.4 | -2.0% |
| Medi Caps Ltd. | 31 | — | 0.28 | -9.21% |
| Vivimed Labs Limited | 46 | — | -0.22 | — |
| Mangalam Drug & Chem Ltd | 50 | — | 0.49 | -35.2% |
| Ortin Global Limited | 12 | — | — | — |
| Sunil Healthcare Ltd. | 78 | 21.1 | 1.12 | 6.01% |
Which Mutual Funds Hold Gkb Ophthalmics Ltd.?
Frequently Asked Questions about Gkb Ophthalmics Ltd.
Gkb Ophthalmics Ltd. (GKB) closed at ₹68.54 on NSE on 25 September 2026, up 0.86 (1.27%) from the previous close.
Gkb Ophthalmics Ltd. trades on the NSE (National Stock Exchange of India) under the symbol GKB.
Gkb Ophthalmics Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 9.69.
Gkb Ophthalmics Ltd. has a dividend yield of 0.0%.
Gkb Ophthalmics Ltd.'s 52-week high is ₹76.9 and its 52-week low is ₹45.2.
Gkb Ophthalmics Ltd. has a market capitalisation of ₹36 crore.
Gkb Ophthalmics Ltd. has a TopFund Quality Score of 59/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Gkb Ophthalmics Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.